News Related to Scribe Therapeutics

Related coverage linked through entity extraction aliases.

Eli Lilly Advances Oral GLP-1 Orforglipron With China Investment and Pipeline Expansion

Mar 16, 2026

Eli Lilly is preparing for the launch of oral weight loss pill Orforglipron with a US$3 billion, decade-long investment in China, while advancing its oncology and genetic medicine pipeline with positive Phase 3 results for Retevmo and a milestone in CRISPR collaboration.

CRISPR Market Projected to Grow 24.1% as Companies Hit Milestones, Launch New Technologies

Feb 24, 2026

The global CRISPR and prime editing market is forecast to grow at 24.1% CAGR through 2031, driven by therapeutic advances and regulatory progress. Scribe Therapeutics achieved a second milestone with Eli Lilly, while new RNA production and gene editing technologies accelerate research.